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Summary
We have investigated the contribution of CDK4 and CDK2 inhibition to G1 arrest in colon cancers following inhibition of
the MEK/MAP kinase pathway. CDK4 inhibition is sufficient to cause arrest, but inhibition of CDK2 by p27 Kip1 redistribution
or ectopic expression has no effect on proliferation. Likewise, inhibition of CDK2 through expression of dominant-negative
(DN) CDK2 or antisense oligonucleotides did not prevent cell proliferation in these cells. We therefore tested whether
CDK2 activity is dispensable in other cells. Surprisingly, osteosarcomas and Rb-negative cervical cancers continued to
proliferate after depletion of CDK2 through antisense oligonucleotides or small interfering (si) RNA. Here we report of
sustained cell proliferation in the absence of CDK2, and we suggest that CDK2 is not a suitable target for cancer therapy.
Introduction Katayose et al., 1997; Blain et al., 1997; Cheng et al., 1999;
Yang et al., 2001), although exceptions have been reported
(Naruse et al., 2000). However, there is little consensus on theGenetic alterations in the Rb pathway are a hallmark of cancer
critical substrates of CDK2 (reviewed in Reed, 1997). Rb appearsand have revealed a number of possible therapeutic targets,
to be a target (Hinds et al., 1992), though the sites of phosphory-including the cyclin-dependent kinases CDK4 and CDK2 (Sherr
lation have been controversial (Zarkowska and Mittnacht, 1997).and Roberts, 1999; Malumbres and Barbacid, 2001). CDK4 ac-
Other substrates for CDK2 include the centrosome proteintivity is clearly implicated in cancer by alterations in its cyclin
nucleophosmin and proteins involved in DNA replication (OkudaD partner and its regulator p16 Ink4a, as well as mutations in
et al., 2000; Nigg, 2001; Stucke et al., 2002). However, it hasCDK4 itself (Sherr and McCormick, 2002), whereas CDK2 is not
not yet been proven that phosphorylation is necessary for prolif-affected directly by mutations or gene copy number changes
eration of mammalian cells in culture. In Xenopus extracts, CDK2that cause cancer (Sherr and Roberts, 1999). It is currently
is necessary for sustaining multiple rounds of DNA replication,believed that progression through the cell cycle from G1 to S
but in the initial round, other kinases such as aurora kinase mayphase requires sequential activation of CDK4 and CDK2 (Sherr
be sufficient (Nigg, 2001). However, in mammalian somatic cells,and Roberts, 1999; Malumbres and Barbacid, 2001). The role
CDK2 may be regulated differently and in cancer cells, auroraof CDK4 is well established: it phosphorylates the Rb protein
kinase and related enzymes are often misregulated or overex-and releases E2F activity (Reed, 1997). E2F in turn activates
pressed (Reed, 1997; Bischoff et al., 1998; Nigg, 2001).transcription of a number of genes involved in regulating and
In this paper, we report that CDK2 activity is dispensable
mediating DNA synthesis (Herrera et al., 1996). CDK4 activity
for cancer cell proliferation. We will discuss the possibility that
is dispensable in cells lacking the Rb protein: many cancer cells, high levels of CDK4 activity in these cells may compensate for
for example, fail to express Rb through sporadic mutation of requirement of CDK2 during cell cycle progression and also
the Rb gene, and these cells fail to growth arrest in the presence suggest that in Rb-minus tumor cells, both CDK4 and CDK2
of CDK4 inhibitors (Lukas et al., 1995a, 1995b; Koh et al., 1995; may be unnecessary for proliferation.
Madema et al., 1995). On the other hand, the function of CDK2
is less clear. A dominant-negative (DN) form of CDK2 prevents Results
growth of cells in culture (van den Heuvel and Harlow, 1993;
Hu et al., 2001), and microinjection of antibodies against CDK2, cyclin D1, cyclin D3, CDK4, and p21 Cip1 proteins
cyclin E, or cyclin A block initiation of DNA synthesis in mamma- are depleted by treatment of colon carcinoma
lian cells (Ohtsubo et al., 1995; Pagano et al., 1992; Tsai et al., cells with MEK inhibitors, resulting
1993). Furthermore, expression of the CDK2 inhibitor p27 Kip1 in complete loss of CDK4 activity
generally causes growth arrest (Polyak et al., 1994; Toyoshima Inhibitors of the Ras/Raf/MEK/MAP kinase pathway are cur-
rently undergoing clinical evaluation, based on their ability toand Hunter, 1994; Kwon and Nordin, 1997; Dirks et al., 1997;
S I G N I F I C A N C E
This paper reports of sustained cell proliferation in the absence of CDK2 activity. Cyclin E/CDK2 activity is frequently increased in
tumors, but it is not clear that this is a cause or a consequence of the disease since there is little consensus on the biochemical targets
of CDK2. Rb appears to be a target, but, as shown here, CDK4 is able to phosphorylate Rb even at CDK2 preferred phosphorylation sites.
We propose that increased levels of CDK4 or E2F activity in cancer cells may compensate for the requirement for CDK2 activity.
These results show that CDK2 is not a suitable target for treatment of cancers, and also question the role of CDK2 in cell proliferation.
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Figure 1. cyclin D1, cyclin D3, CDK4, and p21
Cip1 are strongly suppressed by the MEK inhibitor
U0126 in colon carcinoma cells
Exponentially growing SW480 cells were treated
with DMSO (Control) or 10 M MEK inhibitor
U0126. Cells were collected at the indicated
times (0, 12, 24, 48, and 72 hr) after treatment.
Seventy-two hours with parentheses () indicates
that U0126 was withdrawn at 48 hr and collected
at 72 hr to show that the effect is reversible. West-
ern blots were performed. Phosphorylated
(phospho)-ERK was completely suppressed by 10
M MEK inhibitor U0126. Positive control (pc) from
cell lysates of HeLa cells was used to detect p16
Ink4a expression. Phosphorylation status for the
endogenous Rb expression was analyzed with
total Rb antibody and Rb phosphorylation anti-
bodies specific to CDK4 (6).
inhibit growth of cancer cells, particularly those derived from transduction pathway for the G1/S transition in colon carcinoma
cells (Sebolt-Leopold et al., 1999).colon cancers. However, the mechanisms by which they medi-
ate their effects are not clear (Sebolt-Leopold et al., 1999). We To address the molecular mechanism of G1 arrest following
MEK inhibition, we analyzed expression levels of known cellexamined the mechanism of action of U0126 and PD 184352,
two structurally unrelated compounds that selectively inhibit cycle regulators (Figure 1). After 12 hr of treatment with U0126,
when cells were growth arrested in G1, phosphorylated-ERKMEK1 and MEK2 (Favata et al., 1998; Sebolt-Leopold et al.,
1999; Davies et al., 2000). First, we performed flow cytometric had disappeared, indicating that MEK activity was completely
inhibited. We observed a dramatic reduction of cyclin D1, cyclincell cycle analysis of various colon cancer cells after U0126
treatment. Cells accumulated in G1 within 12 hr of treatment D3, CDK4, and p21 Cip1 during this period of exposure to
U0126. After 48 hr, cyclin A, cyclin E, and CDK1 (CDC2) levelswith U0126 or PD 184352. No sub-G1 phase population was
observed, indicating that cells did not undergo apoptosis (data had also decreased, but CDK2 expression was relatively stable.
Over this time course, no difference was observed in expressionnot shown). The MAP kinase cascade is therefore a key signal
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Figure 2. p27 Kip1 redistribution from CDK4 to
CDK2 and CDK2 kinase inhibition by U0126 in
SW480 cells
A–C: Immunoprecipitation and Immunoblotting
analysis. Cells were collected at indicated time
points (0, 24, and 48 hr). Protein was precipitated
with rabbit antibodies (2 g for each reaction)
specific to CDK2, 4, 6, or p27 Kip1, respectively.
Immune complexes were resuspended and sub-
jected to SDS-PAGE. Immunoblotting was per-
formed using indicated mouse monoclonal anti-
bodies.
A: Samples precipitated with CDK4 or CDK6 anti-
body were loaded onto the same gel.
B: Dissociated p27 Kip1was redistributed from
CDK4 and 6 to CDK2 by U0126.
C: p27 Kip1 redistribution from CDK4 to CDK2 was
shown on the same blot by using p27 Kip1 anti-
body for immunoprecipitation.
D: CDK2-associated Histone H1 kinase assay.
of CDK6 or p27 Kip1. p16 Ink4a was not expressed in these Redistribution of p27 Kip1 from CDK4 to CDK2
following loss of cyclinD/CDK4, resultingcells, probably because its promoter is hyper-methylated (Burri
et al., 2001). Cyclin D2 was not detected in SW480, SW48, in inhibition of CDK2
Redistribution of Cip/Kip family members following increasesDLD-1, and HCT 116 colon cancer cells (data not shown). Similar
results were obtained in SW480 cells with PD 184352 (data not in expression of Ink4 (inhibitors of CDK4) proteins has been
described previously (Reynisdottir and Massague, 1997; Jiangshown). Growth arrest may therefore be caused by downregula-
tion of either cyclin D1, cyclin D3, CDK4, or p21 Cip1 since et al., 1998; McConnell et al., 1999; Swarbrick et al., 2000).
More recently, it was reported that rapid proteolysis of cyclinlevels of these proteins decreased within the 12 hr time period
in which G1 arrest occurred. All of these molecules are essential D1 leads to release of p21Cip1 from CDK4 to inhibit CDK2
activity (Agami and Bernards, 2000). Binding of displaced Cip/for active complexes of cyclin D/CDK4. Inhibition of CDK4 ki-
nase activity was therefore expected (Sherr and Roberts, 1999; Kip proteins to CDK2 and consequent inhibition of CDK2 kinase
activity are thought to contribute to growth arrest mediated byMalumbres and Barbacid, 2001). To confirm this, we tested the
phosphorylation status of the endogenous Rb protein particu- these inhibitors. A recent report from analysis of CDK4 knockout
mice suggests a model for p27 Kip1 redistribution (Tsutsui etlarly for CDK4 (6) phosphorylation sites, Ser780 and Ser795
(Kitagawa et al., 1996; Brugarolas et al., 1999). CDK4 phosphor- al., 1999). Furthermore, overexpression of cyclin D1 and cyclin
D2 resulted in sequestration of p21 Cip1 and p27 Kip1 (Perez-ylation sites on Rb were strongly inhibited by inhibition of MEK
activity. These effects preceded changes in the level of total Roger et al., 1999; Bouchard et al., 1999). These observations
suggest that loss of expression of cyclin D/CDK4 complexesRb itself (see 12, 24, and 48 hr). U0126 was withdrawn after 48
hr and replaced with fresh medium for a further 24 hr. These results in redistribution of p27 Kip1 to inhibit CDK2 kinase activ-
ity. To address the possibility that p27 Kip1 was redistributedsamples are referred to as (72 hr) in the figure; clearly the effects
of U0126 on these cell cycle regulators are completely reversible. from CDK4 and 6 to CDK2 following MEK inhibition, we per-
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Figure 3. p27 Kip1 does not cause the G1 arrest in HCT 116 colon cancer cells
Samples were collected at 24 hr after the simultaneous induction with Ponasterone A (A–F) and U0126 (F). Indicated concentration of Ponasterone A
(Pona A) was used for the gene expression (A–F and H). Immunoblotting was performed (A and B).
A: p27 kip1 ecdysone-inducible (IND) HCT 116 cell lines. Parental HCT 116 cells show the level of endogenous protein.
B: Dose-dependent induction of p27 Kip1 ectopic expression. Double arrow denotes Myc-27. Single arrow denotes endogenous p27 Kip1.
C: Immunoprecipitation and Immunoblotting on p27 Kip1 overexpression in HCT 116 cells.
D: CDK4-associated Rb kinase assay and CDK2-associated histone H1 kinase assay on p27 Kip1-overexpressed HCT 116 cells. Samples were coprecipitated
either with CDK4, CDK2, or control IgG antibodies, respectively.
E–G: Flow cytometric cell cycle analysis.
E and G: Cell cycle distribution after p27 Kip1 induction in HCT 116 cells
F: Combination of U0126 and p27 Kip1 had no effect on the cell cycle profile.
G: p27 kip1 IND HCT 116 line #1 cells were serum starved for 48 hr in the absence () or presence () of 10 M Ponasterone A and then stimulated by
the addition of 10% FBS containing media with or without 10 M Ponasterone A to allow synchronous progression. Samples were collected at indicated
time points.
formed immunoprecipitation and immunoblotting analysis on performed immunoprecipitation with antibodies against CDK2
to test association with p27 Kip1. There was a significant in-CDKs to look for associated regulatory molecules (Figures 2A–
crease in association of p27 Kip1 with CDK2 after treatment2C). In panel A, CDK4 or CDK6 coprecipitated samples were
with U0126 (Figure 2B). This observation was confirmed byanalyzed on the same blot. As expected from Figure 1, cyclin
immunoprecipitation with p27 Kip1. Redistribution of p27 Kip1D1, cyclin D3, and p21Cip1 were not associated with CDK4 or
from CDK4 to CDK2 with U0126 is shown on the same blot6 after 24 hr because of reduced expression (Figure 2A). CDK6
(Figure 2C). Almost identical results were obtained from HCTexpression was not affected significantly by U0126, but reduced
116 cells (data not shown). To investigate the effects of redistri-
association of p27 Kip1 with CDK6 suggested that p27 Kip1 bution of p27 Kip1 to CDK2, we tested CDK2-associated His-
could not bind to CDK6 in the absence of MEK/MAPK activity. tone H1 kinase assay following U0126 treatment (Figure 2D).
p27 Kip1 completely disappeared from CDK4 and 6 after expo- After 24 hr, CDK2 activity was strongly inhibited by U0126.
sure to U0126, although total p27 Kip1 expression was not We conclude that CDK4 activity was inhibited through loss of
changed (Figure 1). An apparent preference of cyclin D1 and expression in cyclin D1, cyclin D3, CDK4, and p21 Cip1. CDK2
p27 for CDK4 relative to CDK6, in contrast to the behavior of activity was inhibited through redistribution of p27 Kip1 (summa-
rized in Figure 9).cyclin D3 and p21, enhanced this effect (Figure 2A). We also
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Overexpression of p27 Kip1 does not cause growth Kip 1 induction (Figure 4A). In the colony-forming assay, cells
expressed ectopic p27 Kip1 for 2 weeks, and colonies werearrest in colon cancers
To establish the relative importance of inhibiting CDK4 and stained with crystal violet (Figure 4B). The number and size of
colonies formed in the presence of ectopic expression of p27CDK2 activity, we generated a p27 Kip 1 ecdysone-inducible
system in HCT 116 colon carcinoma cells (Figures 3A–3D). Over- Kip1 were similar to control. These data strongly suggest that
colon cancer cells proliferate without CDK2 activity and thatexpression of p27 Kip1 induces G1 arrest by altering CDK2
activity in Mv1Lu mink epithelium, Saos-2, HeLa, mouse embryo redistribution of p27 Kip1 to CDK2 following MEK inhibition is
dispensable for G1 arrest. This was confirmed by combiningfibroblasts, U343 astrocytomas, MDA-MB-231 breast cancer
cells, H322, A549, and SQ-5 lung cancer cells (Polyak et al., U0126 with p27 Kip1 induction (Figure 3F). U0126 induced G1
arrest in a dose-dependent manner as mentioned above. How-1994; Toyoshima and Hunter, 1994; Kwon and Nordin, 1997;
Dirks et al., 1997; Katayose et al., 1997; Blain et al., 1997; Cheng ever, no enhancement was seen by p27 Kip1 expression. Similar
results were obtained from another line, #8 (data not shown).et al., 1999; Yang et al., 2001), though no effect was seen in
other cancer cells, such as H69 and Lu-135 lung cancer cells Thus, MEK inhibitors do not require redistribution of p27 Kip1
to cause G1 arrest in colon cancer cells. Indeed U0126 induced(Naruse et al., 2000). We expected that overexpression of p27
Kip1 would cause G1 arrest in colon cancers without addition G1 arrest at 12 hr without altering CDK2 activity in growing
SW480 colon cancer cells (Figure 2D). To address whetherof U0126. We generated two cell lines (#1 and #8) in which p27
Kip1 was highly inducible (Figure 3A). Ectopic expression was CDK4 kinase inhibition is sufficient to induce G1 arrest in colon
cancer cells, we used a CDK4 inhibitor AG12275 to block CDK4distinguished from endogenous expression by the reduced mo-
bility of the c-myc epitope tagged p27 Kip1 protein. Analysis kinase activity (Toogood, 2001; Figures 4C and 4D). We used
AG12275 rather than p16 Ink4a to inhibit CDK4 because smallof a nonexpressing line (#9) and parental cells shows that the
endogenous p27 Kip1 expression was not affected by the ecdy- molecule CDK4 inhibitors are thought to inhibit kinase activities
without changing assembly of cyclin D/CDK4 complexes (seesone analog Ponasterone A (Figures 3A and 3B). Panel B shows
that ectopic expression of p27 Kip1 was induced by Ponaster- Buolamwini, 2000 for review of CDK inhibitors). First, we evalu-
ated the selectivity of CDK4 kinase inhibition. Figure 4C showsone A in a dose-dependent manner. To test whether ectopic
expression of p27 Kip1 was functional, we performed immuno- that AG12275 severely inhibited CDK4 activity; in the same sam-
ples, CDK2 kinase activity was not affected. AG12275 has beenprecipitation and immunoblotting analysis and kinase assay on
both CDK 4 and CDK2 (Figures 3C and 3D). Ectopically ex- demonstrated to inhibit growth of HCT 116 colon carcinoma in a
mouse xenograft model (Toogood, 2001). This was confirmedpressed p27 Kip1 was bound to both CDK4 and CDK2, but the
majority associated with CDK2. Panel D shows that induced by flow cytometric cell cycle analysis with cultured cells (Figure
4D). To test whether p27 Kip1 redistribution was dispensableexpression of p27 Kip1 caused a similar severe inhibition of
CDK2 activity, as seen following treatment with U0126; in the for growth arrest, we treated cells by combining AG12275 with
p27 Kip1 induction. AG12275 induced G1 arrest in a dose-same samples, CDK4 kinase activity was not affected. These
results are in agreement with previous reports cited above and dependent manner; however, little enhancement was seen by
p27 Kip1 expression, suggesting that partial inhibition of CDK4indicate that ectopic expression of p27 Kip 1 in HCT 116 cells
was functional and comparable in activity to endogenous p27 did not render these cells sensitive to CDK2 inhibition. Thus,
inhibition of CDK4 kinase activity but not CDK2 is responsibleKip1 shown in Figures 3A–3D. In addition, expression of myc-
tagged p27 Kip1 did cause growth arrest in U-2 OS osteosar- for G1 arrest in colon cancer cells, and CDK2 activity in these
cells is not sufficient to support S phase entry in the absencecoma, T98G glioblastoma, and C33A cervical carcinoma cells
as described below (Figure 6A). of CDK4 activity.
We analyzed the cell cycle profile 24 hr after induction of
p27 Kip1 (Figure 3E). Surprisingly, ectopic expression of p27 p27 Kip1 expression is not necessary for growth
inhibition by MEK inhibitorsKip1 did not cause growth arrest: no accumulation in G0/G1
and sub-G1 phase population was observed, although we de- To investigate the possibility that p27 Kip1 is dispensable for
G1 arrest in these colon carcinoma cells, we used p27 kip1tected a slight change in S and G2/M phases. Furthermore, there
was no difference in cell cycle profile among cells expressing antisense (AS) oligonucleotides to block p27 Kip1 protein pro-
duction and then assessed the ability of U0126 to cause a G1different levels of p27 Kip1 induced by Ponasterone A. Very
similar results were obtained from another line, #8 induced with arrest in the setting of diminished p27 Kip1 protein level. First,
we evaluated levels of p27 Kip1 protein after the AS oligonucleo-Ponasterone A for 24 or 48 hr (data not shown). To determine
whether overexpression of p27 Kip1 had any effects on cell tides transfections. Growing SW480 cells were transfected ei-
ther with mismatch (MM) oligonucleotide or p27 kip1 AS oligo-cycle progression from quiescence, p27 kip1 IND HCT 116 line
#1 cells were serum starved for 48 hr in the presence or absence nucleotide (Figure 4E). p27 kip1 AS oligonucleotide but not MM
oligonucleotide reduced levels of p27 Kip1 protein more thanof Ponasterone A and then stimulated by the addition of 10%
FBS containing media with or without Ponasterone A to allow 95%. The effect was specific as the similar protein p21 Cip1
was not affected. To determine effects on cell growth, flowsynchronous progression (Figure 3G). Overexpression of p27
Kip1 did not show any delay throughout a complete cell cycle, cytometric cell cycle analysis was performed. Twenty-four hours
after the transfection with either MM oligonucleotide or p27suggesting that CDK2 is not necessary in the initial round of
the cycle. We therefore tested the possibility that CDK2 is not kip1 AS oligonucleotide, SW480 cells were synchronized to G1
phase by serum starvation for overnight and then stimulated bynecessary for sustaining multiple rounds of DNA replication.
Viable cell numbers were counted for a week (Figure 4A) and the addition for the next 12 hr of 10% FBS containing media with
or without U0126 (Figures 4F–4H). The effect was significant,a colony-forming assay was performed (Figure 4B). No differ-
ences were observed in the number of viable cells after p27 as MAPK activity was inhibited by U0126, and p27 kip1 AS
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Figure 4. p27 Kip1 expression is not necessary for growth inhibition in colon cancer cells
Ten micromolar Ponasterone A (Pona A) was used for gene expression (A). Immunoblotting was performed (A). Samples were collected at 24 hr after the
simultaneous induction with Ponasterone A (D) and AG12275 (C and D).
A: Viable cell number from p27 kip1 IND HCT 116 line #1 cells after Ponasterone A inducition. Cells cultured without () or with () 10 M Ponasterone A
were collected at the indicated days (0, 1, 2, 3, 4, 5, 6, 7 days) after induction and stained with trypan blue. Cell number was counted with a haemocytometer.
During the time course, cells were continuously producing high levels of p27 Kip1 proteins (see the above Western blot).
B: Colony formation assay on p27 kip1 IND HCT 116 line #1 cells in the absence () or presence () of 10 M Ponasterone A. One hundred single cells
from p27 kip1 IND HCT 116 line #1 were cultured in the absence () or presence () of Ponasterone A. Fourteen days after induction, cells were stained
with 0.5% crystal violet containing 20% ethanol. Tripricate cell cultures are shown.
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oligonucleotide resulted in recovery of CDK2 kinase activity ments functions as described in previous reports (van den Heu-
vel and Harlow, 1993), we transfected U-2 OS, T98G, and C33A(Figures 4F and 4G). As we expected, p27 kip1 AS oligonucleo-
cells with DN CDK2. Significant increases in G0/G1 in U-2 OStide did not restore growth arrest significantly, although a slight
and T98G cells were detected, as previously reported. C33Arestoration was observed (Figure 4H): U0126 induced a growth
cells were slightly affected, but HCT 116 and SW480 colonarrest both in the MM oligonucleotide- and p27 kip1 AS oligonu-
cancer cells showed no effect. Myc-tagged p27 also causedcleotide-transfected cell cultures. Similar data were obtained
arrest in U-2 OS, T98G, and C33A cells (Figure 6A). To addressfrom the samples treated with U0126 for 24 hr in SW480 and
whether CDK4 kinase inhibition is sufficient to induce G1 arrestHCT 116 cells (data not shown). These results indicate that p27
in colon cancer cells in this system, two forms of DN cdk4Kip1 expression was not responsible for growth inhibition by
expression vector were tested in HCT 116 and SW480 colonMEK inhibitors, and that restoration of CDK2 activity was not
cancers and then we evaluated the effect by flow cytometricsufficient to overcome the effects of MEK inhibition.
cell cycle analysis (Figure 6B). One encodes D158N cdk4, an
analogous form of D145N cdk2. The other encodes T172A cdk4,A dominant-negative form of CDK2 does not cause
in which the activating threonine residue at position 172 in thegrowth arrest in colon cancer cells
T loop is replaced with alanine (Kato et al., 1994a, 1994b; Matsu-To confirm that CDK2 kinase inhibition does not cause growth
oka et al., 1994). The latter form binds cyclin D1 efficiently butarrest in colon cancer cells, we established a D145N DN form
does not phosphorylate the Rb protein (Coleman et al., 1997).of CDK2 in an ecdysone-inducible system. Overexpression of
T160A cdk2 corresponds to the T172A mutant of cdk4. Signifi-a DN CDK2 has been reported previously to induce G1 arrest
cant increases in G0/G1 were detected with either p16 ink4ain U-2 OS and Saos-2 osteosarcomas, T98G glioblastoma, and
or T172A DN cdk4 transfection, but other DN forms did notC33A cervical carcinoma cells (van den Heuvel and Harlow,
show any effect. The effects of DN T172A cdk4 and p16 ink4a1993; Hu, et al., 2001). This protein is thought to inhibit endoge-
confirm the observation using AG12275 that inhibition of CDK4nous CDK2 activity by sequestering cyclin E. We generated four
kinase activity but not CDK2 is responsible for G1 arrest in colonSW480 cell lines (#24, #32, #34, and #43) in which DN CDK2
cancer cells.was highly inducible, out of 50 drug-resistant colonies that we
tested (Figure 5A). Similar to the p27 Kip1-inducible system,
Cancer cells proliferate despite CDK2 inhibition
ectopic expression was distinguished from endogenous expres-
To confirm that CDK2 kinase activity is dispensable in colon
sion by the reduced mobility of the HA epitope-tagged DN CDK2
cancers, we directly inhibited CDK2 kinase activity by depletion
protein. Figure 5A shows that ectopic expression of DN CDK2 of CDK2 expression through antisense (AS) oligonucleotides
was inducible by Ponasterone A. Induced expression of DN and then assessed the effect on cell cycle profile (Figures 7A
CDK2 severely inhibited CDK2 activity (Figure 5B), in agreement and 7B). First, we evaluated levels of CDK2 protein after the
with previous reports (van den Heuvel and Harlow, 1993). How- AS oligonucleotide transfections. Growing SW480, HT-29,
ever, ectopic expression of DN CDK2 did not prevent progres- SW48, and HCT 116 colon cancer cells were transfected either
sion through the cell cycle after release from serum starvation, with mismatch (MM) oligonucleotide or cdk2 AS oligonucleotide
although a delay in S phase entry was observed (Figure 5C). (Figure 7A). cdk2 AS oligonucleotide but not MM oligonucleotide
Likewise, dose-dependent induction of DN CDK2 had little effect significantly reduced levels of CDK2 protein. This was confirmed
on the cell cycle profile of proliferating SW480 cells (clone #24), by Histone H1-associated CDK2 kinase assay. To determine
though a decrease in S phase and an increase in G0/G1 was effects on cell growth, flow cytometric cell cycle analysis was
detected (Figure 5D). Very similar results were obtained from performed after 48 hr from the transfection with either MM
another line, #32 (data not shown). These data strongly support oligonucleotide or cdk2 AS oligonucleotide. As we expected,
the suggestion that CDK2 inhibition does not cause growth depletion of CDK2 expression did not cause growth arrest:
arrest in human colon cancer cells. Furthermore, partial inhibi- no accumulation in G0/G1 and sub-G1 phase population was
tion of CDK4 by AG12275 did not render SW480 cells sensitive observed. We conclude that CDK4 (6) activity is critical to colon
to CDK2 inhibition (Figure 5E). Similar results were obtained cancer cell proliferation, but CDK2 activity is not. We therefore
from another line, #32 (data not shown). Thus, CDK2 kinase activity tested that CDK2 activity is dispensable in other cells (Figures
is dispensable for G1/S transition in colon carcinoma cells. 7C and 7D). Four cancer cell lines were tested: U-2 OS osteosar-
coma cells, C33A and HeLa cervical cancers, and Saos-2 osteo-To confirm that the DN CDK2 construct used in these experi-
C and D: The CDK4 inhibitor AG12275 induced growth arrest in HCT 116 colon carcinoma cells.
C: AG12275 selectively inhibits CDK4 kinase activity. CDK4-associated Rb kinase activity and CDK2-associated histone H1 kinase activity were measured
in extracts from HCT 116 cells (Ponasterone A minus). Synchronized cells were treated with either DMSO (0) or 0.6 M AG12275, respectively. Samples were
coprecipitated with either CDK4 or two antibodies.
D: Flow cytometric cell cycle analysis treated with indicated concentration of AG12275 and Ponasterone A. Percentage of G0/G1 population was shown.
Little enhancement was seen by p27 Kip1 expression.
E–H: p27 Kip1 is not required for the U0126-induced growth arrest.
E: Western blot analysis using lysates from SW480 colon carcinoma cells. Growing cells were treated with indicated concentration of either mismatch (MM)
oligonucleotide or p27 kip1 antisense (AS) oligonucleotide and cultured in the medium for 24 hr.
F–H: Synchronized SW480 cells were treated with combination of DMSO or U0126, and MM oligonucleotide () or p27 kip1 AS oligonucleotide (). Cells
were cultured in the medium for 24 hr.
F: Histone H1-associated CDK2 kinase assay.
G: Western blot analysis.
H: Cell cycle distribution after p27 Kip1 depletion in SW480 cells.
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Figure 5. CDK2 activity is dispensable for G1/S
transition in colon cancers
A–D: Expression of D145N DN form of CDK2 did
not cause growth arrest in colon cancers.
A: DN CDK2 ecdysone-inducible (IND) SW480 cell
lines.
B: CDK2-associated histone H1 kinase assay on
DN CDK2-overexpressed SW480 cells. Samples
were coprecipitated with either CDK2 or control
IgG antibody.
C–E: Flow cytometric cell cycle analysis.
C: DN cdk2 IND SW480 line #24 cells were serum
starved for 48 hr in the absence () or presence
() of 10 M Ponasterone A and then stimulated
by the addition of 10% FBS containing media
with or without 10 M Ponasterone A to allow
synchronous progression. Samples were col-
lected at indicated time points.
D: Cell cycle distribution after DN CDK2 induction
in SW480 cells.
E: Combination of AG12275 and DN CDK2 had
no effect on the cell cycle profile.
sarcomas. First, we evaluated levels of CDK2 protein and their #2 siRNA for HeLa and Saos-2 cells (Figure 7D). To our surprise,
kinase activities after 48 hr from transfections either with AS not only Rb-positive cells (U-2 OS) but Rb-negative cells (C33A,
oligonucleotides or small interfering (si) RNA. Growing U-2 OS HeLa and Saos-2) failed to growth arrest at G0/G1 following
and C33A were transfected either with mismatch (MM) oligonu- depletion of CDK2 (Heise et al., 1997). This was confirmed
cleotide or cdk2 AS oligonucleotide (Figure 7C). cdk2 AS oligo- by counting viable cell numbers: no difference was observed
nucleotide but not MM oligonucleotide significantly reduced between MM and AS or control (#5) and siRNA (#2) transfected
levels of CDK2 protein. As transfections of MM oligonucleotides cultures (data not shown). This suggests that sustained prolifer-
showed toxicity in both HeLa and Saos-2 cells, we therefore ation is possible in the absence of CDK2 protein. Furthermore,
tested RNA interference on these cells (Figure 7C). We gener- U-2 OS cells were treated with the combination of AG12275
ated four cdk2 siRNA double-stranded oligonucleotides. Among
with AS cdk2 (Figure 8A). AG12275 induced G1 arrest in a dose-these, #2 cdk2 siRNA significantly reduced expression of CDK2
dependent manner; however, little enhancement was seen byprotein and its kinase activity. Transfection of #5 cdk2 siRNA
depletion of CDK2 expression through AS cdk2, suggesting thatshows that the endogenous CDK2 expression was not affected;
partial inhibition of CDK4 did not render U-2 OS cells sensitivewe therefore used #5 siRNA as a control for transfection in the
to CDK2 inhibition. We suggest that growth inhibition by DNfurther experiments. To determine effects on cell growth, flow
CDK2 reported previously and confirmed above must be duecytometric cell cycle analysis was performed after 48 hr from
to effects on other components of the cell cycle. For example,the transfection with either MM oligonucleotide or cdk2 AS
oligonucleotide for U-2 OS and C33A cells, or #5 (control) or DN CDK2 could sequester p21 Cip1 or p27 Kip1 proteins that
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Figure 6. Growth arrest by DN CDKs
A: Growth arrest by a DN CDK2 or Myc-tagged
p27Kip1. Cycling HCT 116 and SW480 colon can-
cers, U-2 OS osteosarcomas, T98G glioblastomas,
and C33A cervical cancers were transfected
with either 7.5 g pcDNA3 or either D145N DN
cdk2 or Myc-tagged p27 kip1 pcDNA3 expres-
sion vector with 2.5 g pMACS Kk (Miltenvy
Biotec).
B: Growth arrest by a DN CDK4. Cycling HCT 116
and SW480 colon cancers were transfected with
either 7.5 g pcDNA3, p16 ink4a, D145N or T160A
DN cdk2, or D158N or T172A DN cdk4 pcDNA3
expression vector with 2.5 g pMACS Kk.
A and B: The cells were harvested 24 or 48 hr
after transfection and subsequently stained with
propidium iodide (PI) containing buffer. Flow
cytometric cell cycle analysis was performed
with cells expressing the truncated H–2Kk.
serve as assembly factors for cyclin D/CDK complexes in these phorylation of Rb on Ser807/811 similar to dephosphorylation
of Rb as a whole, suggesting that in these Rb-positive cells,cells. In addition, DN CDK2 has been shown to inhibit CDK1
through association with Cyclin B (Hu et al., 2001). increased levels of CDK4 activity induced by MAPK and/or
-catenin may make cdk2 redundant (Tetsu and McCormick,
CDK4 is able to phophorylate Rb even at CDK2 1999). To test whether other cdks associate with cyclin A or
preferred phosphorylation sites cyclin E following depletion of CDK2, we immunoprecipitated
A Recent model showed that phosphorylation of Rb is triggered these cyclins and measured associated kinase activity. Using
by CDK4 (6) kinases and probably completed by CDK2 kinases Histone H1 as a substrate, we were unable to detect other
as cells enter S phase (Cheng et al., 1999). As partial inhibition associated kinase activities (Figure 8C). In addition, we were
of CDK4 did not render cancer cells sensitive to CDK2 inhibition able to show that Rb-negative C33A cells were able to proliferate
in HCT 116, SW480, and U-2 OS cells, we tested the possibility continuously in the absence of either CDK2 or CDK4 activity
that CDK4 activities compensate requirements of CDK2 activi- (Figure 8D).
ties for Rb phosphorylation (Figures 4D, 5E, and 8A). We as-
Discussionsessed the phosphorylation status of endogenous Rb protein
particularly for CDK2 phosphorylation sites, Ser807/811, where
their phosphorylation is thought necessary for G1-S transition CDK4 activity may make CDK2 redundant in colon
cancer cells(Brugarolas et al., 1999). We treated cells by combining
AG12275 with p27 Kip1 induction in HCT 116, DN cdk2 induc- In this report, we show that CDK2 activity is dispensable for
growth of mammalian cells. CDKs was inhibited or depleted bytion in SW480, or AS cdk2 transfection in U-2 OS (Figure 8B).
Inhibition of CDK4 but not CDK2 significantly reduced phos- overexpression of p27 Kip1, expression of DN CDK2, antisense
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Figure 7. Proliferation of cancer cells does not
depend on CDK2 activity
A and B: CDK2 activity is dispensable in colon
cancers. Growing SW480, HT-29, SW48, and HCT
116 colon carcinoma cells were treated with 300
nM of either mismatch oligonucleotide () or
cdk2 antisense () oligonucleotide and cultured
in the medium for 48 hr.
A: Western blots analysis (CDK2 and -actin) and
CDK2-associated histone H1 kinase assay (kinase
activity).
B: Flow cytometric cell cycle analysis.
C and D: CDK2 activity is dispensable in osteosar-
comas and cervical cancers. Growing U-2 OS
osteosarcoma cells and C33A cervical cancer
cells were treated with 300 nM of either mis-
match oligonucleotide () or cdk2 antisense ()
oligonucleotide and cultured in the medium for
48 hr. Growing HeLa cervical cancer cells and
Saos-2 osteosarcoma cells were treated with
mock (m) or 120 nM of #2 () or #5 () cdk2
small interfering (si) RNA doublestrand oligonu-
cleotides and cultured in the medium for 48 hr.
C: Western blots analysis (CDK2 and -actin) and
CDK2-associated histone H1 kinase assay (kinase
activity).
D: Flow cytometric cell cycle analysis.
oligos against cdk2, or by siRNA. Previous reports implicating nase, which were identified as centrosomal substrates for CDK2
(Okuda et al., 2000; Stucke et al., 2002). Interestingly, centro-an essential role for CDK2 in cancer cells relied on effects of
DN constructs and expression of p27 Kip1: here we suggest some amplification in tumors has been linked to genetic changes
in the p53 pathway, including mutations in p53 itself, its regula-that these proteins have additional effects that are not related
directly to CDK2 inhibition. Substrates for CDK2 include Rb and tors MDM2, and downstream targets p21 Cip1 and Gadd45
(Nigg, 2001; Tarapore et al., 2001). All colon cancer cells andproteins involved in centrosome duplication. However, it has
not been shown that phosphorylation of these substrates by U-2 OS cells we studied here have mutations in either p53 or the
MDM2 regulator p14ARF (Heise et al., 1997; Burri et al., 2001).CDK2 is essential for cell cycle progression. Here we show that
phosphorylation of CDK2-preferred recognition sites Ser807/ Centrosome amplification was also observed in response to
overexpression of aurora-A kinase (Zhou et al., 1998). Aurora-A811 on Rb occurs in the absence of CDK2. These cancer cells
have high levels of CDK4 activity, through loss of p16 INK4a, kinase is overexpressed in cell lines and primary colon cancers
including SW480 cells (Bischoff et al., 1998). Taken together,upregulation of cyclin D1 (through Ras and -catenin signaling),
and expression of the assembly factor p21 Cip1: perhaps for we suggest that CDK2 activity is dispensable for both DNA
replication and centrosome duplication in these Rb-positive co-these reasons, CDK4 is able to phosphorylate Rb on CDK2-
preferred sites (Figure 8B). lon cancer cells. Antisense (AS) cdk2 and siRNA experiments
in this report suggest that CDK2 activity may also be unneces-We also suggest that the requirement of CDK2 activity for
centrosome duplication is reduced in colon cancer cells. Re- sary in Rb-negative cells, although we believe further studies are
required to resolve this issue. We conclude that CDK2 activity iscently, it has been shown that CDK2 is required for duplication
of the centrosome and spindle pole body, particularly for phos- dispensable in cancer cells and that selective CDK2 inhibition
does not offer a promising strategy for cancer therapeutics.phorylation of nucleophosmin NO38/B23 and Mps1 protein ki-
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Figure 8. Proliferation of cancer cells despite
CDK2 inhibition
A: Combination of AG12275 and AS cdk2 in U-2
OS cells had no effects on the cell cycle profile.
B: CDK4 phophorylates Rb at CDK2 preferential
phosphorylation sites Ser807/811. Phosphoryla-
tion status for the endogenous Rb expression was
analyzed with total Rb antibody and Rb phos-
phorylation antibodies specific to CDK2. pRb
and ppRb stands for nonphosphorylated and
phosphorylated forms of Rb, respectively. Cells
were treated in the combination of AG12275
with p27 Kip1 induction in HCT 116, DN cdk2 in-
duction in SW480, or AS cdk2 transfection in U-2
OS. Ten micromolar of Ponasterone A and 0.6
M of AG12275 were used.
C and D: C33A cells proliferate despite CDK2,
CDK4, and CDK6 inhibition.
C: cyclin A, cyclin E, and CDK2 associated his-
tone H1 kinase assays on AS cdk2-treated C33A
cells. C33A cells were treated with either MM ()
or AS cdk2 (). Samples were coprecipitated
either with cyclin A, cyclin E, CDK2, or control
IgG antibodies.
D: Colony formation assay in the combination of
AG12275 and AS cdk2 in C33A cells. One hun-
dred single cells from C33A were cultured in the
absence () or presence () of AG12275 and
MM or AS cdk2. Cultured after 21 days, cells were
stained with 0.5% crystal violet containing 20%
ethanol. Triplicate cell cultures are shown.
Experimental procedures tides directed against p27 kip1 (CTCCGCTAACCCCGTCTGGC) and 8 bp
mismatch oligonucleotides (CGCCTCGACCCACTTCGGTC), and cdk2 (TGC
GATAACAAGCTCCGTCC) and 8 bp mismatch oligonuleotides (GGCTACChemicals, site-directed mutagenesis, cell culture,
and establishment of inducible cell lines AATATGCACTGCCC), were synthesized as described previously (Gottschalk
et al., 2001; ISIS Pharmaceuticals). Antisense and mismatch oligonucleotidesThe MEK inhibitors, U0126 (Promega) and PD 184352 (Calbiochem and
Upstate), the CDK4 inhibitor AG12275, and the ecdysone analog Ponaster- were transfected by using Lifofectin (Invitrogen). cdk2 small interfering (si)
RNA oligonucleotide target sites were selected and generated as recom-one A (Invitrogen) were suspended in DMSO. CDK T loop mutant forms,
T160A cdk2 and T172A cdk4, were generated using QuickChange site- mended (Xeragon, www.xeragon.com). siRNAs were transfected by using
Oligofectamine (Gibco, Invitrogen).directed mutagenesis kit according to the instructions (Stratagene). SW480,
HT-29, SW 48, DLD-1, HCT 116, U-2 OS, T98G, Saos-2, HeLa, and C33A
were obtained from the American Type Culture Collection. Ecdysone-induc- Western blot analysis
Protein was prepared with cell lysis buffer 50 mM Tris HCl (pH 8.0), 120ible cell lines were established using the Ecdysone-Inducible Mammalian
Expression System (Invitrogen). pIND-inducible expression vector resistant mM NaCl, 0.25%NP-40, and 0.1% SDS containing the protease inhibitor
cocktail, Complete Mini (Roche) to obtain whole-cell lysates. Twenty micro-to Hygromycine which contains either myc epitope-tagged p27 kip1 and
HA epitope-tagged D145N DN cdk2 was transfected by using FuGENE6 grams of protein were loaded onto a sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). Eight (Rb blotting) or Twelve percent (oth-(Roche) upon HCT 116 or SW480 cell lines carrying ecdysone response
receptor, respectively (Wakita et al., 2001). Ten or fifty single-cell derived ers) acrylamide gel was used. Western blots were developed by enhanced
chemiluminescence (Amersham). Following monoclonal and polyclonal pri-independent drug-resistant colonies were cloned and screened for each
gene. Exogenous expression levels of each of these genes were monitored mary and secondary antibodies, horseradish peroxidase (HRP) conjugated
antibodies were used. Active (phosphorylated)-ERK (Promega, E-4, Santaby Western blotting. The highest induced gene expression cell line was
chosen for further study. Chimeric phosphorothioate antisense oligonucleo- Cruz), Pan (p42 and 44)-ERK (Promega), cyclin A (C-19, Santa Cruz), cyclin
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